Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Adverse effects · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Quantity of drinking (g/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. binges/wk) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Completion of treatment · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: baclofen versus clonidine compared with other pharmacological detoxification treatment (very low certainty).
4 findings from 1 review
RR 1.06 [0.63, 1.8]
66 participants
Very low
RR 2.01 [1.69, 2.38]
361 participants
Low
RR 0.95 [0.65, 1.37]
72 participants
Very low
Show 1 more finding
Withdrawal symptoms · management of opium withdrawal
4 findings from 1 review
Show 1 more finding
no estimate extracted
34 participants
Very low
Completion of treatment: clonidine versus clonidine plus amantadine, inpatient setting · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus clonidine plus amantadine,… compared with other pharmacological detoxification treatment (very low certainty).
1 finding from 1 review
RR 1.03 [0.86, 1.24]
69 participants
Very low
Completion of treatment: clonidine versus buprenorphine, inpatient setting · management of opium withdrawal
It is very uncertain whether pharmacological detoxification treatment changes completion of treatment: clonidine versus buprenorphine, inpatient… compared with other pharmacological detoxification treatment (very low certainty).
1 finding from 1 review
RR 1.04 [0.9, 1.2]
35 participants
Very low
Completion of treatment: methadone versus methadone plus gabapentin · management of opium withdrawal
Pharmacological detoxification treatment showed no clear difference in completion of treatment: methadone versus methadone plus gabapentin compared with other pharmacological detoxification treatment (low certainty).
1 finding from 1 review
Depression severity: final score (interviewer‐rated scales) · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Response to antidepressive treatment · people with co‐occurring depression and alcohol dependence
It is very uncertain whether antidepressants changes response to antidepressive treatment compared with placebo: all studies (very low certainty).
1 finding from 1 review
Percent of days abstinent · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Consumption of alcohol: abstinent participants (number) · people with co‐occurring depression and alcohol dependence
Antidepressants probably leads to higher consumption of alcohol: abstinent participants (number) compared with placebo: all studies (moderate certainty).
1 finding from 1 review
Amount of alcohol consumed, short term (3‐6 months) measured using the number of drinks/drinking day (in past week to 30 days) · people with co‐occurring depression and alcohol dependence
1 finding from 1 review
Acceptability ‐ total dropouts · people with co‐occurring depression and alcohol dependence
Antidepressants showed no clear difference in acceptability: dropouts compared with placebo: all studies (low certainty).
1 finding from 1 review
Tolerability of treatment: withdrawal for medical reasons · people with co‐occurring depression and alcohol dependence
Antidepressants showed no clear difference in tolerability of treatment: withdrawal for medical reasons compared with placebo: all studies (low certainty).
1 finding from 1 review
Maximum number of weeks of consecutive alcohol abstinence during treatment · concurrent problem alcohol and illicit drug users
1 finding from 1 review